Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Resource Type
Academic Journal
Authors
Bai X; Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, China.; Massachusetts General Hospital, USA.; Shaheen A; Newcastle University Centre for Cancer, UK.; Grieco C; Skin Unit, The Royal Marsden NHS Foundation Trust, London, UK.; d'Arienzo PD; Skin Unit, The Royal Marsden NHS Foundation Trust, London, UK.; Mina F; Skin Unit, The Royal Marsden NHS Foundation Trust, London, UK.; Czapla JA; Massachusetts General Hospital, USA.; Lawless AR; Massachusetts General Hospital, USA.; Bongiovanni E; Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Italy.; Santaniello U; Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Italy.; Zappi H; Alfred Health, Australia.; Dulak D; Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Williamson A; The Christie NHS Foundation Trust, Manchester, UK.; Lee R; Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UK.; Gupta A; The Christie NHS Foundation Trust, Manchester, UK.; Li C; Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, China.; Si L; Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, China.; Ubaldi M; University of Perugia, Italy.; Yamazaki N; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.; Ogata D; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.; Johnson R; Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.; Park BC; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.; Jung S; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.; Madonna G; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.; Hochherz J; Department of Dermatology, University Medical Center Hamburg-Eppendorf (UKE), University Skin Cancer Center, Hamburg, Germany.; Umeda Y; Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.; Nakamura Y; Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.; Gebhardt C; Department of Dermatology, University Medical Center Hamburg-Eppendorf (UKE), University Skin Cancer Center, Hamburg, Germany.; Festino L; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.; Capone M; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.; Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.; Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.; Lo SN; Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney, North Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Long GV; Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.; Menzies AM; Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.; Namikawa K; Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.; Mandala M; University of Perugia, Italy.; Guo J; Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, China.; Lorigan P; Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UK.; Najjar YG; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Haydon A; Alfred Health, Australia.; Quaglino P; Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Italy.; Boland GM; Massachusetts General Hospital, USA.; Sullivan RJ; Massachusetts General Hospital, USA.; Furness AJS; Skin Unit, The Royal Marsden NHS Foundation Trust, London, UK.; Plummer R; Newcastle University Centre for Cancer, UK.; Flaherty KT; Massachusetts General Hospital, USA.
Source
Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE